Overview
The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Cancer Steering Committee (BC-CSC) annually convenes more than 200 experts from academia, pharmaceutical companies, biotechnology companies, not-for-profit organizations, the National Cancer Institute (NCI), the U.S. Food and Drug Administration (FDA) and other federal agencies to focus on biomarker discovery and development across the cancer landscape. The Symposium offers a unique opportunity to prioritize and strategize future directions in biomarker discovery and development. Attendees have an opportunity to explore cutting-edge science, hear feature presentations from experts, brainstorm critical areas of biomarker research need and pitch collaborations designed to inform the field of exciting new advances.
Topic areas covered include a focus on early diagnosis, difficult to detect tumor types, regulatory hurdles and advancements, analytical validation and clinical utility of liquid biopsy, project opportunities around immune oncology biomarkers, cross-disease analysis of biomarker initiatives in microbiome and Minimal Residual Disease in blood-based cancers and technological progress in AI and imaging. The Symposium highlights the importance of public-private partnership with updates from ongoing pre-competitive BC-CSC projects, as well as provides dedicated networking opportunities to explore potential new collaborations.
Partners
Public-Sector Partners
- National Cancer Institute
- Society for Immunotherapy of Cancer (SITC)*
- U.S. Food and Drug Administration (FDA)
Private Sector Partners
- Adaptive Biotechnologies*
- Alkermes, Inc.*
- Genmab US, Inc.*
- Ikena Oncology*
- Janssen Oncology*
- PathAI, Inc.*
- Pfizer, Inc.*
- Regeneron Pharmaceuticals, Inc.*
- Sengenics*
- Takeda Pharmaceuticals U.S.A., Inc.*
*Provides financial or in-kind support for this program.
Goals
- Discuss cutting edge science, including projects supported by the FNIH BC.
- Inform the field of the latest developments in critical areas of biomarker science.
- Guide CSC decision making and project planning.
For more information on how to partner with us, please contact [email protected].
FNIH Contacts
- Dana E. Connors
Director, Translational Science
Cancer
Associate Director, Biomarkers Consortium
[email protected] - Althea Lang, PhD
Senior Project Manager, Translational Science
Cancer
[email protected] - Stacey J. Adam, PhD
Vice President, Science Partnerships
Translational Science
[email protected] - Marina Milan
Project Manager, Translational Science
Cancer
[email protected]
Media
Results & Accomplishments
Stimulating Interdisciplinary Communication and Collaboration
- Each year, the Symposium showcases diverse projects across the ecosystem of precision medicine and biomarker development, including those focused on minimal residual disease (MRD), liquid biopsy, novel imaging, cell-free RNA and DNA Research and immune oncology. Cross-disease analysis of noncancer biomarker initiatives also helps to spur interdisciplinary collaborations across medicine.
For more information on how to partner with us, please contact [email protected].